134 related articles for article (PubMed ID: 11966439)
1. Benzamide riboside, a recent inhibitor of inosine 5'-monophosphate dehydrogenase induces transferrin receptors in cancer cells.
Szekeres T; Sedlak J; Novotny L
Curr Med Chem; 2002 Apr; 9(7):759-64. PubMed ID: 11966439
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity and characterization of an active metabolite of benzamide riboside, a novel inhibitor of IMP dehydrogenase.
Gharehbaghi K; Paull KD; Kelley JA; Barchi JJ; Marquez VE; Cooney DA; Monks A; Scudiero D; Krohn K; Jayaram HN
Int J Cancer; 1994 Mar; 56(6):892-9. PubMed ID: 7907081
[TBL] [Abstract][Full Text] [Related]
3. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.
Jayaram HN; Cooney DA; Grusch M; Krupitza G
Curr Med Chem; 1999 Jul; 6(7):561-74. PubMed ID: 10390601
[TBL] [Abstract][Full Text] [Related]
4. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.
Gharehbaghi K; Sreenath A; Hao Z; Paull KD; Szekeres T; Cooney DA; Krohn K; Jayaram HN
Biochem Pharmacol; 1994 Oct; 48(7):1413-9. PubMed ID: 7945441
[TBL] [Abstract][Full Text] [Related]
5. Studies on the mechanism of action of benzamide riboside: a novel inhibitor of IMP dehydrogenase.
Gharehbaghi K; Grünberger W; Jayaram HN
Curr Med Chem; 2002 Apr; 9(7):743-8. PubMed ID: 11966437
[TBL] [Abstract][Full Text] [Related]
6. Potential mechanisms of benzamide riboside mediated cell death.
Polgar D; Gfatter S; Uhl M; Kassie F; Leisser C; Krupitza G; Grusch M
Curr Med Chem; 2002 Apr; 9(7):765-71. PubMed ID: 11966440
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of the novel IMP dehydrogenase inhibitor benzamide riboside.
Jäger W; Salamon A; Szekeres T
Curr Med Chem; 2002 Apr; 9(7):781-6. PubMed ID: 11966442
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of benzamide riboside in vitro and in vivo.
Novotny L; Rauko P; Yalowitz JA; Szekeres T
Curr Med Chem; 2002 Apr; 9(7):773-9. PubMed ID: 11966441
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells.
Jayaram HN; Gharehbaghi K; Jayaram NH; Rieser J; Krohn K; Paull KD
Biochem Biophys Res Commun; 1992 Aug; 186(3):1600-6. PubMed ID: 1354960
[TBL] [Abstract][Full Text] [Related]
10. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
Jayaram HN; O'Connor A; Grant MR; Yang H; Grieco PA; Cooney DA
J Exp Ther Oncol; 1996 Sep; 1(5):278-85. PubMed ID: 9414415
[TBL] [Abstract][Full Text] [Related]
11. The chemistry of nicotinamide adenine dinucleotide (NAD) analogues containing C-nucleosides related to nicotinamide riboside.
Pankiewicz KW; Watanabe KA; Lesiak-Watanabe K; Goldstein BM; Jayaram HN
Curr Med Chem; 2002 Apr; 9(7):733-41. PubMed ID: 11966436
[TBL] [Abstract][Full Text] [Related]
12. Benzamide riboside induces apoptosis independent of Cdc25A expression in human ovarian carcinoma N.1 cells.
Grusch M; Rosenberger G; Fuhrmann G; Braun K; Titscher B; Szekeres T; Fritzer-Skekeres M; Oberhuber G; Krohn K; Hengstschlaeger M; Krupitza G; Jayaram HN
Cell Death Differ; 1999 Aug; 6(8):736-44. PubMed ID: 10467347
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cytotoxicity of benzamide riboside by expression of NMN adenylyltransferase.
Yalowitz JA; Jayaram HN
Curr Med Chem; 2002 Apr; 9(7):749-58. PubMed ID: 11966438
[TBL] [Abstract][Full Text] [Related]
14. Staurosporine enhanced benzamide riboside-induced apoptosis in human multidrug-resistant promyelocytic leukemia cells (HL-60/VCR) in vitro.
Hunáková L; Duraj J; Romanová D; Novotný L; Sedlák J; Kelley MR; Szekeres T; Jayaram HN; Chorváth B
Neoplasma; 1998; 45(4):204-9. PubMed ID: 9890662
[TBL] [Abstract][Full Text] [Related]
15. Benzamide riboside induced mitochondrial mediated apoptosis in human lung cancer H520 cells.
Khanna N; Jayaram HN; Singh N
Life Sci; 2004 May; 75(2):179-90. PubMed ID: 15120570
[TBL] [Abstract][Full Text] [Related]
16. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents.
Franchetti P; Grifantini M
Curr Med Chem; 1999 Jul; 6(7):599-614. PubMed ID: 10390603
[TBL] [Abstract][Full Text] [Related]
17. Role of human nucleoside transporters in the cellular uptake of two inhibitors of IMP dehydrogenase, tiazofurin and benzamide riboside.
Damaraju VL; Visser F; Zhang J; Mowles D; Ng AM; Young JD; Jayaram HN; Cass CE
Mol Pharmacol; 2005 Jan; 67(1):273-9. PubMed ID: 15486050
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and efficacy of benzamide riboside in cancer chemotherapy models.
Jayaram HN; Yalowitz JA; Arguello F; Greene JF
Curr Med Chem; 2002 Apr; 9(7):787-92. PubMed ID: 11966443
[TBL] [Abstract][Full Text] [Related]
19. A second target of benzamide riboside: dihydrofolate reductase.
Roussel B; Johnson-Farley N; Kerrigan JE; Scotto KW; Banerjee D; Felczak K; Pankiewicz KW; Gounder M; Lin H; Abali EE; Bertino JR
Cancer Biol Ther; 2012 Nov; 13(13):1290-8. PubMed ID: 22954684
[TBL] [Abstract][Full Text] [Related]
20. Synergistic growth inhibitory and differentiating effects of trimidox and tiazofurin in human promyelocytic leukemia HL-60 cells.
Szekeres T; Fritzer M; Strobl H; Gharehbaghi K; Findenig G; Elford HL; Lhotka C; Schoen HJ; Jayaram HN
Blood; 1994 Dec; 84(12):4316-21. PubMed ID: 7994048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
